[go: up one dir, main page]

MX2022001680A - Proteinas de fusion contra glucoesfingolipidos sialosilados y glucoproteinas sialiladas, y usos de los mismos. - Google Patents

Proteinas de fusion contra glucoesfingolipidos sialosilados y glucoproteinas sialiladas, y usos de los mismos.

Info

Publication number
MX2022001680A
MX2022001680A MX2022001680A MX2022001680A MX2022001680A MX 2022001680 A MX2022001680 A MX 2022001680A MX 2022001680 A MX2022001680 A MX 2022001680A MX 2022001680 A MX2022001680 A MX 2022001680A MX 2022001680 A MX2022001680 A MX 2022001680A
Authority
MX
Mexico
Prior art keywords
fusion proteins
glycosphingolipids
sialosylated
sialylated
proteins against
Prior art date
Application number
MX2022001680A
Other languages
English (en)
Inventor
Francis V A Fernandes
Original Assignee
On Target Molecules Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by On Target Molecules Biotech Inc filed Critical On Target Molecules Biotech Inc
Publication of MX2022001680A publication Critical patent/MX2022001680A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a proteínas de fusión contra un glucocálix, en asociación con varias proteínas humanas con modificación postraduccional vinculadas a líneas de células cancerosas. Las proteínas de fusión de la presente invención son capaces de unirse a glucoesfingolípidos sialilados y glucoproteínas sialiladas, así a como sus constituyentes independientes, los azúcares monosacáridos tales como neu5ac, galnac y gal que constituyen el glucocálix. Los productos reclamados pueden utilizarse para el diagnóstico y tratamiento de diversos cánceres. La apoptosis mediante caspasa 3 tiene lugar en células cancerosas cuando la proteína de fusión, unida a los objetivos, se secuestra en los lisosomas. La proteína de fusión no se observa en ningún otro orgánulo de la célula, excepto los lisosomas.
MX2022001680A 2019-08-08 2020-08-07 Proteinas de fusion contra glucoesfingolipidos sialosilados y glucoproteinas sialiladas, y usos de los mismos. MX2022001680A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962884585P 2019-08-08 2019-08-08
PCT/US2020/045481 WO2021026491A1 (en) 2019-08-08 2020-08-07 Fusion proteins against sialosylated glycosphingolipids and sialated glycoproteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2022001680A true MX2022001680A (es) 2022-03-11

Family

ID=72234957

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001680A MX2022001680A (es) 2019-08-08 2020-08-07 Proteinas de fusion contra glucoesfingolipidos sialosilados y glucoproteinas sialiladas, y usos de los mismos.

Country Status (4)

Country Link
US (1) US20250353901A1 (es)
EP (1) EP4010012A1 (es)
MX (1) MX2022001680A (es)
WO (1) WO2021026491A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
JP2006526382A (ja) * 2002-12-06 2006-11-24 シンガポール ジェネラル ホスピタル ピーティーイー リミテッド 中枢神経系の損傷
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
WO2007011856A2 (en) * 2005-07-15 2007-01-25 The Trustees Of Columbia University In The City Of New York Compositions and methods for differential diagnosis of chronic lymphocytic leukemia
WO2010019921A2 (en) * 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
WO2013101509A2 (en) * 2011-12-15 2013-07-04 Alternative Innovative Technologies Llc Hsp70 fusion protein conjugates and uses thereof
US20190345255A1 (en) * 2016-09-19 2019-11-14 The University Of Toledo Monoclonal igm antibodies from entirely carbohydrate constructs

Also Published As

Publication number Publication date
US20250353901A1 (en) 2025-11-20
WO2021026491A1 (en) 2021-02-11
EP4010012A1 (en) 2022-06-15

Similar Documents

Publication Publication Date Title
MX2017003989A (es) Alfa-glucosidasa acida altamente potente con carbohidratos mejorados.
MX2024000006A (es) Proteinas de fusion inmunomoduladoras y sus usos.
BR112017018919A8 (pt) Proteínas de fusão imunomoduladoras e seus usos
BR112012006388A2 (pt) célula de vertebrado para produzir uma molécula, método para produzir uma molécula, molécula, composição, proteína ou lipídeo, unidade de expressão, célula eucariótica para produzir uma proteína, e, método para produzir uma proteína
CL2022001785A1 (es) Composiciones alimenticias con alto contenido de proteínas
BR112018001260A2 (pt) mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição.
BR112014018630A2 (pt) alvejamento de glicanos de sulfato de condroitina
IL244326A0 (en) Activation of inkt cells using glycolipids with modified glucose groups
MX2015007846A (es) Anticuerpos anti-b7-h4 humana y sus usos.
BR112014006455A2 (pt) alquilamidotiazóis, preparações cosméticas ou dermatológicas com um teor de um ou vários alquilamidotiazóis e uso de um ou vários alquilamidotiazóis
MX2020001344A (es) Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
ECSP13013118A (es) Composiciones de lípidos algales y métodos para prepararlas y utilizarlas
BR112016027830A2 (pt) composições de fibra e de carboidrato, produto alimentício, métodos de produção de composição de fibra, de elaboração de composição de carboidrato misturada, de redução do índice glicêmico e de inibição da elevação do nível de açúcar no sangue, composição cosmética, uso da composição de fibra e composição
MX2017003592A (es) Sacaridos y mezclas y composiciones de sacaridos.
BR112017017538A2 (pt) maltooligossacarídeos ricos em fibra que têm biodisponibilidade de glicose baixa, método de fabricação dos mesmos e uso dos mesmos em alimento humano e alimentação animal
BR112016015105A2 (pt) Conjugados var2csa-droga
MX2017008923A (es) Glicoproteinas recombinantes sialiladas con o-glicano y lineas de celulas para producir las mismas.
BR112016027839A2 (pt) composições de fibra e de carboidrato, produto alimentício, métodos de produção de composição de fibra, de elaboração de composição de carboidrato misturada, de redução do índice glicêmico de alimentos ou bebidas e de inibição da elevação do nível de açúcar no sangue, composição cosmética, uso da composição de fibra e produto
AR078858A1 (es) Proteinas encapsulantes de lipidos neutros modificadas y sus usos
BR112014029346A2 (pt) sistema e método implementado por computador para a montagem de um plano de tratamento médico
MX2021002294A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en pd-1.
BR112015017227A2 (pt) método de produção de licor preto e método de produção para líquido que contém um componente de sabor
BR112014021602A2 (pt) uso, kit e derivado de retinal sintético para melhorar a função visual em distúrbios visuais associados com a deficiência de produção endógena de retinóide
MX2017011510A (es) Proteinas lisosomales glicosiladas, metodo de produccion y usos.
AR095334A1 (es) Composiciones nutricionales que contienen un componente peptídico con propiedades estimulantes de la adiponectina y método para promover un peso corporal saludable